Exalpha Biologicals, Inc.

Latest News

Exalpha Biologicals, Inc. is now a US distributor for Nordic-Mubio products

Nordic-MUbio develops and manufactures high quality antibody reagents for use in R&D. All our products are manufactured according to strict ISO 9001 quality guidelines, and our focus is on developing antibodies targetting Cell Adhesion, Nuclear and Cytoskeletal Proteins.

Nordic-MUbio is one of the leading antibody companies developing antibodies for zebrafish research – we currently have over 50 antibodies validated for immunofluorescence in zebrafish.

Learn More

Latest References

Akazawa, Y., et al. "Endoplasmic Reticulum Stress Contributes to Helicobacter Pylori VacA-Induced Apoptosis" PLoS ONE 8(12): e82322

Learn More

Homa, N.J., et al. "Epstein-Barr Virus Induces Global Changes in Cellular mRNA Isoform Usage That Are Important for the Maintenance of Latency" J. Virol., 2013, 87, 12291-12301

Learn More

COMBI IC Reagent: Mouse anti Myeloperoxidase-C2 (FITC) and Mouse anti CD22 (PE)

  • Product Code: GIC-214
  • Size: 50 Tests
  • Availability: In Stock In Stock
  • Price (USD): $379

Product Code

GIC-214		 Quantity:      

Data Sheet

Product Name

COMBI IC Reagent: Mouse anti Myeloperoxidase-C2 (FITC) and Mouse anti CD22 (PE)

Size

50 Tests

Price (USD)

$379

Background

Myeloperoxidase (MPO) is a glycoprotein present in the azurophil (primary) granules of myeloid cells, which appears in the myeloblast stage of myeloid cell differentiation. MPO is he most common functional protein of myeloid cells and is involved in the inflammatory response. It helps to kill microbes by breaking down peroxide in the presence of halide ions, contributing to the bactericidal function of granulocytes. The primary translation product of MPO undergoes glycosylation with production of the 89 kDa heme-free apopro-MPO form followed by incorporation of heme and conversion into the enzymatically active pro-MPO form. Subsequently, pro-MPO becomes targeted to azurophil granules where final processing occurs to produce mature dimeric MPO consisting of the 59-64 kDa MPO _-chain and the 14 kDa MPO _-chain. Precursor B-cells are surface-CD22 negative, but cytoplasmic CD22 positive. Mature B-lymphocytes.express CD22 also on their surface. The combined staining for MPO and CD22 allows the distinction of mature/immature myeloid cells and B-lymphocytes. The MPO-C2/CD22 COMBI-IC mAb permits the identification and enumeration of normal and malignant myelomonocytic cells and B lymphoid commited cells in human blood and bone marrow using flow cytometry. Results must be put within the context of other diagnostic tests as well as the clinical history of the patient by a certified professional before final interpretation. Analyses performed with this antibody should be paralleled by positive and negative controls. If unexpected results are obtained which cannot be attributed to differences in laboratory procedures, please contact us.

Clone Name

8E6 and RFB4

Host

Mouse

Isotype

IgG1

Species Reactivity

Human

Product Type

Primary Antibodies

Applications

Permeabilization and Staining Procedure - In combination with our Permeabilization Kit FIX&PERM_ (Cat. No. GAS-002) intracellular MPO-C2 and CD22 can be easily stained in cell suspensions. - For each sample to be analyzed add 50

Product Formulation

PBS pH 7.2, 1 mg/ml BSA, 0.1% NaN3

Storage Conditions

Nordic-MUbio monoclonal antibody reagents contain optimal concentrations of affinity-purified antibody. For stability reasons this monoclonal antibody solution contains sodium azide. These reagents should be stored at 2-8

References

Andersson, E., Hellman, L., Gullberg, U. & Olsson, I. (1998) J Biol Chem 273, 4747-53.
Beverley, P. C., Linch, D. & Callard, R. E. (1981) Haematol Blood Transfus 26, 309-13.
Boue, D. R. & Lebien, T. W. (1988) J Immunol 140, 192-9.
Braylan, R. C., Orfao, A., Borowitz, M. J. & Davis, B. H. (2001) Cytometry 46, 23-7
Catovsky, D., Matutes, E., Buccheri, V., Shetty, V., Hanslip, J., Yoshida, N. & Morilla, R. (1991) Ann Hematol 62, 16-21.
Janossy, G., Coustan-Smith, E. & Campana, D. (1989) Leukemia 3, 170-81.
Knapp, W., Majdic, O. & Strobl, H. (1993) Recent Results Cancer Res 131, 31-40.
Koeffler, H. P., Ranyard, J. & Pertcheck, M. (1985) Blood 65, 484-91.
Konikova, E., Glasova, M., Kusenda, J. & Babusikova, O. (1998) Neoplasma 45, 282-91.
Lanza, F., Latorraca, A., Moretti, S., Castagnari, B., Ferrari, L. & Castoldi, G. (1997) Cytometry 30, 134-44.
Li, J. L., Shen, G. L., Ghetie, M. A., May, R. D., Till, M., Ghetie, V., Uhr, J. W., Janossy, G., Thorpe, P. E., Amlot, P. & et al. (1989) Cell
Immunol 118, 85-99.
Mason, D. Y., Stein, H., Gerdes, J., Pulford, K. A., Ralfkiaer, E., Falini, B., Erber, W. N., Micklem, K. & Gatter, K. C. (1987) Blood
69, 836-40.
Murao, S., Stevens, F. J., Ito, A. & Huberman, E. (1988) Proc Natl Acad Sci U S A 85, 1232-6.